恩替单药治疗的慢性乙肝患者部分病毒学应答的长期影影响

StephenW

http://www.ncbi.nlm.nih.gov/pubmed/22934534##
Scand J Gastroenterol. 2012 Aug 31. [Epub ahead of print]
Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
Ko SY, Choe WH, Kwon SY, Kim JH, Seo JW, Kim KH, Lee CH.
Source

Department of Internal Medicine, Konkuk University School of Medicine , Seoul , Korea.
Abstract

Abstract Objective. Partial virologic response (PVR) in chronic hepatitis B (CHB) patients during antiviral therapy is associated with an increased risk of occurrence of viral resistance and treatment failure. The aim of this study was to evaluate the clinical and virological responses of partial responders to long-term entecavir (ETV) monotherapy. Material and method. In this open-labeled prospective study, 128 treatment-naïve CHB patients treated with 0.5 mg ETV once daily for more than 12 months were monitored at baseline and at 3-month intervals during treatment. Results. At baseline, the mean age of subjects was 47.0 ± 13.0 years, and the median duration of treatment was 27 months; 85 subjects (66.4%) were HBeAg-positive, and 47 patients (36.7%) had liver cirrhosis. Eighteen of 128 patients (14.0%) showed PVR to 48 weeks of ETV treatment, and 13 patients were followed up for over 24 months. Among them, 9 of 13 patients (69.2 %) achieved a complete virologic response (VR, HBV-DNA < 60 IU/mL) during prolonged ETV treatment. Four showed persistent PVR, but only one patient with poor compliance developed genetic resistance to ETV at month 27. The occurrence of PVR was independently associated with a high viral load, more than 7 log(10) IU/mL (p = 0.014). Conclusions. CHB patients with a high viral load, more than 7 log log(10) IU/mL, are related to the occurrence of PVR during ETV monotherapy. Long-term ETV monotherapy may be effective for suppressing serum HBV DNA levels in treatment- naïve CHB patients with a PVR to ETV.

StephenW

Scand胃肠病学杂志。 2012年08月31日。 [EPUB的提前打印]
恩替卡韦单药治疗的慢性乙肝患者恩替卡韦治疗的部分病毒学应答的长期影响。
，李，金，金，权，崔WH高SY SY JH，徐JW KH CH。
源

内科，建国大学医学院，首尔，韩国。
抽象

【摘要】目的。部分病毒学应答（PVR）在慢性乙型肝炎（CHB）患者在抗病毒治疗与病毒耐药性的发生和治疗失败的风险增加。本研究的目的是评估的局部反应，以长期恩替卡韦（ETV）单药治疗的临床和病毒学反应。的材料和方法。在这个开放标记的前瞻性研究，128治疗初治慢性乙肝患者在治疗过程中监测在基线和3个月的时间间隔以0.5 mg ETV治疗，每天一次，超过12个月。结果。在基线时，受试者的平均年龄为47.0±13.0岁，而平均治疗时间为27个月，85例（66.4％），HBeAg阳性，47例（36.7％），肝硬化。 18128例（14.0％），PVR ETV治疗48周，13例患者随访超过24个月。 13例（69.2％），其中9实现了完整的病毒学应答（VR，HBV-DNA<60 IU / mL）中，在长时间的ETV治疗。表现为持续性PVR，但只有一个病人依从性差，开发遗传性ETV在本月27。 PVR的发生，具有高病毒载量，超过7日志（10）IU /毫升（P = 0.014）独立相关。结论。高病毒载量，超过7 log日志（10）IU / mL时，都涉及到PVR的发生在ETV单药治疗慢性乙型肝炎患者。长期ETV单药治疗，可有效抑制血清HBV DNA水平在治疗初治的慢性乙型肝炎患者ETV一个PVR。

咬牙硬挺

好药。无可奈何就吃一辈子

wswlgh

这现在有点后悔吃这个药了，吃了一年。现在说有肝癌了？哭哇，早知道我真不该抗什么病毒了。